Kenji Kuramoto
Chairman bei PHOENIXBIO CO., LTD.
Vermögen: 112 104 $ am 31.03.2024
Profil
Kenji Kuramoto is currently the Chairman at PhoenixBio Co., Ltd.
He previously held the position of Chairman at PhoenixBio USA Corp.
Additionally, he served as the President & Representative Director at Institute of Immunology Co., Ltd.
and as the Manager-Corporate Planning at Sanwa Starch Co., Ltd.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
PHOENIXBIO CO., LTD.
0,87% | 31.03.2023 | 35 200 ( 0,87% ) | 112 104 $ | 31.03.2024 |
Aktive Positionen von Kenji Kuramoto
Unternehmen | Position | Beginn |
---|---|---|
PHOENIXBIO CO., LTD. | Chairman | 28.06.2018 |
Ehemalige bekannte Positionen von Kenji Kuramoto
Unternehmen | Position | Ende |
---|---|---|
Institute of Immunology Co., Ltd.
Institute of Immunology Co., Ltd. Medical SpecialtiesHealth Technology Institute of Immunology Co., Ltd. engages in the manufacture and sale of diagnostic reagents and monoclonal antibodies for research purpose. It develops and produces Enzyme Immunoassay (EIA) kits related to infectious diseases such as hepatitis B as well as those for human hepatocellular growth factor determination. The firm also offers EIA kits for detecting hepatitis E virus antibody and for determining the genotypes of hepatitis B virus and offers immunization of 3 mice, evaluation, fusion, screening, cloning, ascites production and purification services to the research, clinical and medical industries. The company was founded by Tetsuo Nakamura on August 18, 1979 and is headquartered in Tokyo, Japan. | President | 01.01.2006 |
PhoenixBio USA Corp.
PhoenixBio USA Corp. Miscellaneous Commercial ServicesCommercial Services Part of PhoenixBio Co., Ltd., PhoenixBio USA Corp. develops technologies for mass propagation of human cells into laboratory animals. The private company is based in New York, NY. Yoshio Morikawa has been the CEO of the company since 2015. | Chairman | - |
Sanwa Starch Co., Ltd.
Sanwa Starch Co., Ltd. Agricultural Commodities/MillingProcess Industries Sanwa Starch Co., Ltd. manufactures and processes starch and starch products. The firm also manufactures sugar and glucose-based products. The company was founded by Seiichi Morimoto on January 9, 1947 and is headquartered in Kashihara, Japan. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
PHOENIXBIO CO., LTD. | Commercial Services |
Private Unternehmen | 3 |
---|---|
Sanwa Starch Co., Ltd.
Sanwa Starch Co., Ltd. Agricultural Commodities/MillingProcess Industries Sanwa Starch Co., Ltd. manufactures and processes starch and starch products. The firm also manufactures sugar and glucose-based products. The company was founded by Seiichi Morimoto on January 9, 1947 and is headquartered in Kashihara, Japan. | Process Industries |
Institute of Immunology Co., Ltd.
Institute of Immunology Co., Ltd. Medical SpecialtiesHealth Technology Institute of Immunology Co., Ltd. engages in the manufacture and sale of diagnostic reagents and monoclonal antibodies for research purpose. It develops and produces Enzyme Immunoassay (EIA) kits related to infectious diseases such as hepatitis B as well as those for human hepatocellular growth factor determination. The firm also offers EIA kits for detecting hepatitis E virus antibody and for determining the genotypes of hepatitis B virus and offers immunization of 3 mice, evaluation, fusion, screening, cloning, ascites production and purification services to the research, clinical and medical industries. The company was founded by Tetsuo Nakamura on August 18, 1979 and is headquartered in Tokyo, Japan. | Health Technology |
PhoenixBio USA Corp.
PhoenixBio USA Corp. Miscellaneous Commercial ServicesCommercial Services Part of PhoenixBio Co., Ltd., PhoenixBio USA Corp. develops technologies for mass propagation of human cells into laboratory animals. The private company is based in New York, NY. Yoshio Morikawa has been the CEO of the company since 2015. | Commercial Services |